Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Luseogliflozin (TS 071) hydrate, a second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor, exhibits selective potency and oral activity, with an IC50 of 2.26 nM. This compound is utilized in research for the treatment of type 2 diabetes mellitus (T2DM).
产品描述 | Luseogliflozin (TS 071) hydrate, a second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor, exhibits selective potency and oral activity, with an IC50 of 2.26 nM. This compound is utilized in research for the treatment of type 2 diabetes mellitus (T2DM). |
靶点活性 | SGLT2:2.26 nM (IC50) |
体外活性 | Luseogliflozin can increase beta cell proliferation through the activation of the FoxM1/PLK1/CENP-A pathway via humoral factors thats act in an insulin/IGF-1 receptor-independent manner. Luseogliflozin increases beta cell proliferation in OSI-906-treated mice[2]. Cell Viability Assay[2]Cell Line: βIRKO, IRS1KO and IRS2KO beta cells Concentration: 100 nM Incubation Time: 24 and 48 hours Result: Cell Viability Assay[2]Treating cells with serum from the OSI-906 (200 nM) or OSI-906+Luseogliflozin(100 nM) group led to significantly increased cell viability in the latter group in the control, IRS1KO, IRS2KO, as well as the insulin receptor (IR)-deficient βIRKO beta cells. |
体内活性 | SGLT2 inhibition with Luseogliflozin (10 mg/kg/daily; oral gavage) significantly ameliorates hyperglycaemia, but not hyperinsulinaemia, in the OSI-906(45 mg/kg)-treated mice. Luseogliflozin ameliorates hyperglycaemia induced by OSI-906[2]. Animal Model: C57BL/6J male mice aged 8 weeks old[2]Dosage: 10 mg/kg/daily Administration: Oral gavage; for 7 days between 08:00 and 09:00 hours Result: Treatment significantly ameliorated the OSI-906 (45 mg/kg)-induced hyperglycaemia. |
别名 | 鲁格列净水合物, TS 071 hydrate |
分子量 | 452.56 |
分子式 | C23H32O7S |
CAS No. | 1152425-66-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Luseogliflozin hydrate 1152425-66-5 鲁格列净水合物 TS071 Hydrate TS 071 hydrate Luseogliflozin Hydrate TS 071 Hydrate TS-071 Hydrate Inhibitor inhibitor inhibit